You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine. The specific changes are outlined below.
Section 7: Drug Interactions
Antimalarials: artemether/lumefantrine – No change in darunavir exposures. Decrease in artemether and dihydroartemisinin exposures. Increase in lumefantrine exposures. The combination of Prezista and artemether/lumefantrine can be used without dose adjustments. However, the combination should be used with caution as increased lumefantrine exposure may increase the risk of QT prolongation.
Section 12 Clinical Pharmacology was also updated to include these drug interactions.
You can view the complete, revised label at Drugs@FDA.
Prezista is a product of Janssen Pharmaceuticals.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Products
Food and Drug Administration
Steve Morin
Office of Special Health Issues
Food and Drug Administration
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
